# Neuroimaging-AI Endophenotypes of Brain Diseases in the General Population: Towards a Dimensional System of Vulnerability

- 3
- 4 Junhao Wen<sup>1\*</sup>, Ioanna Skampardoni<sup>2</sup>, Ye Ella Tian<sup>3</sup>, Zhijian Yang<sup>2</sup>, Yuhan Cui<sup>2</sup>, Guray Erus<sup>2</sup>,
- 5 Gyujoon Hwang<sup>2</sup>, Erdem Varol<sup>4</sup>, Aleix Boquet-Pujadas<sup>5</sup>, Ganesh B. Chand<sup>6</sup>, Ilya Nasrallah<sup>2</sup>,
- 6 Theodore Satterthwaite<sup>7</sup>, Haochang Shou<sup>2</sup>, Li Shen<sup>8</sup>, Arthur W. Toga<sup>9</sup>, Andrew Zaleskey<sup>3</sup>,
- 7 Christos Davatzikos<sup>2,\*</sup>
- 8 9
- 9 <sup>1</sup>Laboratory of AI and Biomedical Science (LABS), Stevens Neuroimaging and Informatics Institute, Keck School 0 of Medicine of USC, University of Southern California, Los Angeles, California, USA
- 10 of Medicine of USC, University of Southern California, Los Angeles, California, USA
- <sup>11</sup><sup>2</sup>Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated
- 12 Diagnostics (AI<sup>2</sup>D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- 13 <sup>3</sup>Melbourne Neuropsychiatry Centre, Department of Psychiatry, Melbourne Medical School, The University of
- 14 Melbourne, Melbourne, Victoria, Australia
- <sup>4</sup>Department of Computer Science and Engineering, New York University, New York, USA
- 16 <sup>5</sup>Biomedical Imaging Group, EPFL, Lausanne, Switzerland
- 17 <sup>6</sup>Department of Radiology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA
- 18 <sup>7</sup>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- <sup>8</sup>Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School of Medicine,
   Philadelphia, USA
- 21 <sup>9</sup>Laboratory of Neuro Imaging (LONI), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine
- 22 of USC, University of Southern California, Los Angeles, California, USA
- 23
- 24 \*Corresponding authors:
- 25 Junhao Wen, junhaowe@usc.edu
- 26 2025 Zonal Ave, Los Angeles, CA 90033, United States
- 27 Christos Davatzikos, <u>christos.davatzikos@pennmedicine.upenn.edu</u>
- 28 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States
- 29
- 30 Word counts: 5669 words

#### 31 Abstract

- 32 Disease heterogeneity poses a significant challenge for precision diagnostics in both clinical and
- 33 sub-clinical stages. Recent work leveraging artificial intelligence (AI) has offered promise to
- 34 dissect this heterogeneity by identifying complex intermediate phenotypes herein called
- 35 dimensional neuroimaging endophenotypes (DNEs) which subtype various neurologic and
- 36 neuropsychiatric diseases. We investigate the presence of nine such DNEs derived from
- 37 independent yet harmonized studies on Alzheimer's disease (AD1-2)<sup>1</sup>, autism spectrum disorder
- 38  $(ASD1-3)^2$ , late-life depression  $(LLD1-2)^3$ , and schizophrenia  $(SCZ1-2)^4$ , in the general
- 39 population of 39,178 participants in the UK Biobank study. Phenome-wide associations revealed
- 40 prominent associations between the nine DNEs and phenotypes related to the brain and other
- 41 human organ systems. This phenotypic landscape aligns with the SNP-phenotype genome-wide
- 42 associations, revealing 31 genomic loci associated with the nine DNEs (Bonferroni corrected P-
- 43 value  $< 5x10^{-8}/9$ ). The DNEs exhibited significant genetic correlations, colocalization, and causal
- 44 relationships with multiple human organ systems and chronic diseases. A causal effect (odds
- 45 ratio=1.25 [1.11, 1.40], P-value= $8.72 \times 10^{-4}$ ) was established from AD2, characterized by focal
- 46 medial temporal lobe atrophy, to AD. The nine DNEs and their polygenic risk scores
- 47 significantly improved the prediction accuracy for 14 systemic disease categories and mortality.
- 48 These findings underscore the potential of the nine DNEs to identify individuals at a high risk of
- 49 developing the four brain diseases during preclinical stages for precision diagnostics. All results
- 50 are publicly available at: <u>http://labs.loni.usc.edu/medicine/</u>.

#### 51 Main

Disease heterogeneity<sup>2,3,5-10</sup> has been a significant challenge for precision medicine<sup>11</sup>, including 52 53 precision neuroscience. A new era powered by artificial intelligence (AI) and large-scale, multiomics biomarkers may enable us to quantify individualized liability for various brain 54 diseases<sup>12,13</sup>. Recent work has leveraged semi-supervised clustering methods (Fig. 1a and 55 56 Supplementary eMethod 1) to tackle this challenge. These methods characterize the disease 57 heterogeneity by constructing a mapping or transformation from a reference group (e.g., healthy 58 controls) to a target group (i.e., patients with a specific disease). In clinical neuroscience, these 59 methods can quantify deviation from typical brain structure measured by T1-weighted magnetic resonance imaging (MRI)<sup>1-4</sup>. They represent disease-related neuroanatomical heterogeneity via k60 low-dimensional categorical subtypes associated with specific patterns of brain change relative 61 62 to the reference group. Instead of focusing on the k categorical subtypes, we investigated their corresponding continuous phenotypes<sup>14</sup>, given that brain diseases develop along a continuous 63 spectrum. Each neuroanatomical pattern's level of expression, therefore, serves as a dimensional 64 65 AI-derived biomarker pertinent to the respective disease. 66 Previous heterogeneity research has primarily focused on within-disease heterogeneity<sup>2,3,5–10</sup>. However, this approach neglects the shared etiology, genetics, and clinical 67 68 manifestations among different brain diseases. Conversely, while several studies have investigated the shared genetic components across various brain diseases, they have overlooked 69 the important aspect of disease heterogeneity within each condition<sup>15,16</sup>. As such, a broad 70 71 perspective is required to simultaneously investigate disease heterogeneity, spanning multiple 72 neurodegenerative and neuropsychiatric disorders. This holistic approach aids in understanding 73 the commonalities and interrelationships between these brain diseases and multi-organ systems 74 of the human<sup>17,18</sup>. Such an effort could simultaneously capture neurobiological heterogeneity 75 within disorders and explain shared features, mechanisms, and risk factors across disorders. 76 Ultimately, unraveling neurobiological heterogeneity within neuropsychiatric syndromes and 77 explaining co-morbidity among them promises to accelerate more effective diagnosis, treatment, 78 and prevention strategies. 79 Recent work leveraging AI-derived biomarkers identified using semi-supervised learning 80 has offered novel ways to capture complex neuroanatomical heterogeneity within disease

81 populations<sup>2,3,5–9</sup>. However, whether these biomarkers are present in the general population, 82 potentially simultaneously, remains unknown. Here, we sought to measure the presence of multiple AI-based signatures in the general population, delineate common mechanisms among 83 84 them, and shed light on their relationship with numerous human organ systems<sup>17,18</sup>. To do this, 85 we capitalized on nine imaging biomarkers recently derived from regional gray matter (GM) volumetrics derived from several large-scale disease-focused consortia, including ADNI<sup>19</sup> for 86 87 Alzheimer's disease (AD1-2), ABIDE<sup>20</sup> for autism spectrum disorder (ASD1-3), LLD<sup>3</sup> for late-88 life depression older than 65 years old (LLD1-2), and PHENOM<sup>4</sup> for schizophrenia (SCZ1-2). 89 We first conceptualized these biomarkers as the dimensional neuroimaging endophenotype 90 (DNE), seeking to test the endophenotype hypothesis in psychiatry $^{21-23}$ , which suggests that such measurable intermediate biomarkers (i.e., the endophenotypes) serve as intermediate phenotypes 91 92 between genetics and clinical symptoms of the disease. They are thought to be more closely 93 related to the underlying etiology (or genetics) than the complex clinical symptoms or the disease 94 itself.

In this study, we evaluated the manifestation of the nine DNEs in the general population using the extensive and comprehensive multi-omics data available in the UK Biobank study<sup>24</sup>

- 97 (UKBB, Method 1), collected from more than 500,000 participants in the United Kingdom. The
- 98 pre-trained AI models (Method 2) from the four disease populations were applied to the 39,178
- 99 participants with brain MRI<sup>25</sup> and genetic<sup>26</sup> data from the UKBB general population. To
- 100 delineate the phenotypic landscape of the nine DNEs, we first tested whether the
- 101 neuroanatomical patterns of the nine DNEs are present in the UKBB general population.
- 102 Subsequently, we conducted a phenome-wide association study (PWAS, Method 3) to establish
- associations between the nine DNEs and additional 611 UKBB phenotypes, including brain
- 104 imaging-derived phenotypes (IDPs), traits related to multiple human organ systems, cognition,
- and lifestyle factors. To depict their genetic architecture, we performed a genome-wide
- association study (GWAS, **Method 4**) linking the nine DNEs to 6,477,810 quality-checked
- 107 common single nucleotide polymorphisms (SNPs). Furthermore, we conducted analyses to
- 108 investigate genetic correlations, colocalization, and causal relationships between the nine DNEs,
- 109 nine human organ systems, and several chronic diseases. Finally, we assessed the ability of the
- 110 nine DNEs and their corresponding PRSs to predict 14 systemic disease categories and mortality
- 111 (Method 5).
- 112

# 113 **Results**

- 114 Our analytic framework involves computational genomics, statistical methods, and machine
- 115 learning to elucidate the phenotypic landscape and genetic architecture of the nine DNEs, as
- 116 illustrated in **Fig. 1**.

117



#### 118 Figure 1: Study workflow



**a**) The concept of semi-supervised learning methods used in this study (**Method 1**). These AI

121 methods model the patterns and transformations from the healthy control (CN) to the patient 122 (PT) domain, thus capturing variations related to underlying disease pathology. Nine DNEs

previously published<sup>1–4</sup> from four disease-focused, case-control studies were investigated.

including ADNI<sup>19</sup> for Alzheimer's disease (AD1-2), ABIDE<sup>20</sup> for autism spectrum disorder

125 (ASD1-3), LLD<sup>3</sup> for late-life depression older than 65 years old (LLD1-2), and PHENOM<sup>4</sup> for

schizophrenia (SCZ1-2). **b**) The expression of the nine DNEs in the UK Biobank (UKBB)

general population. The trained models were then applied to the UKBB population to quantify

the expression of the neuroanatomical patterns of the nine DNEs at individual levels; a higher

- 129 DNE score indicates a greater expression (manifestation/presence) of the respective
- 130 neuroanatomical pattern. For example, the blue samples express predominantly AD2, whereas
- 131 the pink sample express predominantly SCZ2. The kernel density estimate for each DNE is
- 132 shown. c) Phenome- and genome-wide analyses performed in this study for the nine DENs.
- 133 phenome-wide association studies (PWAS) were conducted to associate the nine DNEs with
- 134 phenotypes across nine organ systems, cognition, and lifestyle factors. Genome-wide association
- 135 studies (GWAS) were performed to investigate associations between the nine DNEs and
- 136 common genetic variants (SNPs). Finally, the nine DNEs and their polygenic risk scores
- 137 predicted 14 disease categories (ICD-10-based) and mortality.
- 138

#### 139 All nine DNEs are evident in the general population

140 We tested whether the neuroanatomical patterns defined in the four disease populations could be

- 141 found in the general population. We applied the DNE models pre-trained for each disease
- 142 population to the UKBB general population to measure the degree of expression of each DNE at
- 143 the individual level.
- We first summarize the neuroanatomical patterns of the nine DNEs (Fig. 2a and Method
  3b). The original patterns identified in the disease populations<sup>1-4</sup> manifest in the general
- 146 population. AD1 exhibits a pattern of brain atrophy (i.e., negative correlation) across various
- 147 brain volumes, while AD2 involves focal atrophy of the medial temporal lobe and hippocampus.
- 148 ASD1 captures a pattern of mildly lower GM volumes in several subcortical regions, including
- the pallidum, amygdala, and putamen, whereas ASD2 reflects a pattern of relatively larger GM
- volumes (i.e., positive correlation) in subcortical regions. ASD3, conversely, is characterized by relatively larger GM volumes in several cortical areas, including the insula. LLD1 (positive
- 151 relatively larger GM volumes in several cortical areas, including the insula. LLD1 (positive) 152 correlation) and LLD2 (negative correlation) are characterized by widespread patterns of
- regional GM volumes, including the middle frontal gyrus, the insula, and the thalamus. For
- schizophrenia, a widespread pattern of reduced brain volumes (e.g., insula) is associated with
- 155 SCZ1, whereas SCZ2 displays increased volumes of the putamen and pallidum. The details of
- the P-value, sample sizes, and  $\beta$  values of the linear regression are presented in **Supplementary**
- 157 **eFile 1** (from disease-specific populations<sup>1-4</sup>) and **2** (from UKBB).
- 158 Compared to the disease populations of the neuroanatomical patterns of the nine DNEs
   159 displayed remarkable deviations in the general population. These deviations were characterized
   160 by significant over- and under-expression, except for ASD2, after correcting for multiple
- 161 comparisons using the Bonferroni method (Fig. 2b). For instance, AD1, characterized by diffuse
- brain atrophy in the ADNI data, showed a significant under-expression (i.e., a smaller mean of
- 163 the DNE score) in the general population. Conversely, the subcortical atrophy pattern originally
- 164 identified in ASD1 from the ABIDE data displayed a significant over-expression (i.e., a larger
- 165 mean of the DNE score) in the participants from the general population.
- 166 These results provided compelling evidence that the nine DNEs are present in the general 167 population. The contrast in their expression (i.e., over- and under-expression) between the 168 disease-specific and UKBB general populations is expected and underscores their potential 169 relevance as sub-clinical or vulnerability quantitative indices.
- 170

# 171 The nine DNEs exhibit phenotypic associations with traits beyond the brain

- 172 To delineate their phenotypic landscape, we associated the nine DNEs with 611 phenotypes in
- 173 UKBB. To avoid circularity, the PWAS did not include the 119 GM ROIs derived from T1-

weighted MRI, from which the nine DNEs were derived. Out of the 611 additional clinical traits
spanning multiple organ systems, cognition, and lifestyle factors, we discovered 1818 significant

176 associations after applying the Bonferroni correction (P-value < 0.5/611) (Fig. 2c,

#### 177 Supplementary eFile 2, and Method 3c).

- 178 Of the 1818 significant associations, 91% were related to the brain. For example, the 179 mean intracellular volume fraction in the superior frontal-occipital fasciculus derived from the
- multi-shell NODDI<sup>28</sup> model was significantly associated with AD1 [ $\beta$ =-0.67±0.02, -log<sub>10</sub>(P-
- value) > 300]. Multiple DNEs were significantly associated with the biological age gap (BAG:
- AI-predicted age minus chronological age) of the brain [e.g., SCZ2:  $\beta$ =0.19±0.01, -log<sub>10</sub>(P-
- 183 value)=50.10]. Furthermore, 2% of the phenotypes related to the musculoskeletal system were
- 184 associated with the nine DNEs. The nine DNEs were also largely associated with many
- 185 phenotypes related to mental health (1%). For example, the neuroticism score was significantly
- 186 associated with LLD2 [ $\beta$ =-1.09x10<sup>-2</sup>±2.42x10<sup>-3</sup>, -log<sub>10</sub>(P-value)=5.20] (Supplementary eFile 3).
- 187 We conducted two sensitivity analyses to validate the main PWAS results (**Method 3c**).
- 188 We obtained high concordance rates in split-sample (98.03%) and sex-stratified analyses
- 189 (93.98%). Detailed results can be found in **Supplementary eText 1** and **Supplementary eFile 4**
- and **5** for split-sample and sex-stratified analyses.
- 191 As anticipated, 91% of the significant associations were linked to the brain, given that the
- 192 DNEs were derived from regional brain volumetrics in brain disease-specific populations.
- 193 However, it is noteworthy that these phenotypic associations extended beyond the brain,
- 194 providing evidence for the significant associations between the brain and the rest of the body.

# 195



#### 196 Figure 2: Phenome-wide associations of the nine DNEs

# 197

a) The neuroanatomical patterns of the nine DNEs were manifested in the UKBB general
 population and were concordant with the patterns initially derived from the original disease

200 populations<sup>1-4</sup>, A linear regression model was applied to the 119 gray matter regions of interest

201 (ROIs) derived from T1-weighted MRI data while accounting for various covariates (Method

202 **3b**). We present the  $\beta$  coefficients of the ROIs that withstood the Bonferroni correction. Positive

203 correlations are depicted using warm reddish colors, while cold blue colors represent negative

- 204 correlations. For AD2, we showed the sagittal view to visualize the hippocampus and medial
- temporal lobe. **b**) The nine DNEs are over-expressed (i.e., a higher mean of the DNE score in the
- 206 population) and under-expressed (i.e., a lower mean of the DNE score) in the general population 207 compared to the disease populations. The kernel density estimates of the nine DNEs are shown
- 207 compared to the disease populations. The kernel density estimates of the nine DNEs are shown 208 for both the training dataset (gray-colored in patients) and the independent test dataset from the
- 209 UK Biobank (UKBB). Significant differences that survived the Bonferroni corrections between
- the training and independent test datasets (two-sampled t-test) are denoted with the symbol \*. c)
- 211 Phenome-wide associations (PWAS) between the nine DNEs (left panel) and 611 phenotypes
- 212 (middle panel) are dominated by brain phenotypic measures. The length of each rectangle block
- 213 indicates the percentage of associations for each DNE or phenotype category. The right panel
- shows representative phenotypes linked to multiple phenotype categories with the highest
- statistical significance after the Bonferroni correction (P-value<0.05/611). A thicker colored line
- corresponds to a higher value of -log10(P-value). The symbols "+" and "-" represent positive and negative correlations.
- 218

# 219 Genome-wide associations identify 66 genomic loci associated with the nine DNEs

220 At the genome-wide significance level (P-value $<5x10^{-8}$ ), GWAS (Method 4a) identified 10, 8, 221 5, 21, 9, 1, 3, 3, and 6 genomic loci significantly associated with AD1, AD2, ASD1, ASD2, 222 ASD3, LLD1, LLD2, SCZ1, and SCZ2, respectively (66 in total, Fig. 3a, and Supplementary eFile 6). At a more stringent significance level (P-value $<5x10^{-8}/9$ ), 31 loci passed the Bonferroni 223 224 correction. Notably, 41 loci are novel - their top lead SNP was not associated with any clinical traits in the EMBL-EBI GWAS Catalog<sup>29</sup>, as annotated in Fig. 3a (Method 4c, query date: 2<sup>nd</sup> 225 226 June 2023, via FUMA version: v1.5.4). To support the robustness of our GWAS, we estimated 227 the intercept of linkage disequilibrium score regression (LDSC)<sup>30</sup> and obtained intercepts of 228 1.003, 1.0314, 0.9969, 1.0155, 1.0129, 1.0131, 1.0166, 1.0109, 1.0127 for the nine DNEs. All 229 intercepts were close to 1, indicating no substantial genomic inflation in our GWASs. The

229 Intercepts were close to 1, indicating no substantial genomic inflation in our GwASs. The 230 Manhattan and OO plots of the nine GWASs are presented in **Supplementary eFigure 2-10**.

All DNEs are significantly heritable  $(0.24 < h^2 < 0.66, P-value < 1x10^{-10})$  after Bonferroni correction (**Fig. 3a, Supplementary eTable 1**, and **Method 4b**). We employed the GCTA<sup>31</sup> software to estimate  $h^2$ , acknowledging that previous research<sup>32,33</sup> has demonstrated variations in the magnitude of  $h^2$  estimates based on the choice of methods.

235 We further investigated the significant genomic loci by mapping them to protein-236 encoding genes and examining their functional implications through expression quantitative trait 237 loci (eQTL) mapping. Supplementary eFigure 1 presents the regional Manhattan plot for the 238 most significant genomic locus associated with each DNE. For example, we identified a locus associated with ASD2 (top lead SNP: rs3068507 at 20q11.21) and a neighboring locus associated 239 240 with SCZ1 (top lead SNP: rs6088962 at 20q11.21), both of which mapped to the MYLK2 gene 241 (Supplementary eFigure 1d and h). MYLK2 encodes a myosin light chain kinase primarily 242 expressed in adult skeletal muscle.

We conducted six sensitivity analyses to validate the main GWAS results (**Method 4a**). Overall, we obtained high concordance rates in split-sample, sex-stratified (63.26-92.54%), and longitudinal GWAS analyses (100%, N=1116), but the concordance rates were relatively low in non-European ancestry GWAS, independent ADNI GWAS, and six case-control GWAS<sup>34–39</sup> of neurodegenerative and neuropsychiatric disorders from the psychiatric genetic consortium. Refer to **Supplementary eText 2** and **Supplementary eTable 2** for details. The sample sizes for the

- 249 non-European (*N*=4783) and ADNI (*N*=1555) samples are small; the case-control GWAS from
- the psychiatric genetic consortium may overlook the heterogeneity within each disease. Detailed
- results are presented in **Supplementary eText 2** for the sensitivity results, **Supplementary eFile**
- 252 **7-12** for replicated SNPs/loci, and **Supplementary eFigures 2-10** for Manhattan and QQ plots
- and the LDSC intercepts. In addition, all GWAS results are also publicly available in the
- 254 MEDICINE web portal: <u>http://labs.loni.usc.edu/medicine/</u>. In conclusion, our GWASs identified
- 255 many novel genomic loci that previous case-control GWASs might have missed.
- 256

#### 257 The genetic associations of the nine DNEs parallel their phenotypic associations

- We performed a phenome-wide look-up analysis (**Method 4d**) to understand the phenotypic associations of these identified genomic loci in the literature.
- 260 In total, 2525 clinical traits were associated with genetic variants in our GWAS,
- 261 including traits linked to multiple organ systems, cognition, and lifestyle factors (Fig. 3b and
- 262 Supplementary eFile 13). The genomic loci were largely associated with clinical traits of the
- brain (53%), musculoskeletal (17%), immune system (6%), neurodegenerative (1%), and
- neuropsychiatric (1%) diseases. For example, AD2 genomic loci were largely associated with
- traits related to the brain (565 out of 781, e.g., IDPs), musculoskeletal (133/781, e.g., standing
- height), immune (17/781, e.g., reticulocyte count), cognition (15/781, e.g., cognitive
- performance), lifestyle factors (13/781, e.g., smoking), and neurodegenerative traits (1/781, i.e.,
  neurofibrillary tangles).
- 269 The findings closely align with the phenotypic associations observed in **Fig. 2c**,
- reinforcing that the DNEs share genetic determinants linked to organs beyond the brain, lifestylefactors, and cognition.



272 Figure 3: Genome-wide associations of the nine DNEs



a) Genome-wide associations identified 66 (10, 8, 5, 21, 9, 1, 3, 3, 6 for the nine DNEs) genomic 275 loci (P-value $<5x10^{-8}$ ) associated with the nine DNEs. Using the top lead SNP, we denoted the 41 276 novel genomic loci - not associated with any clinical traits in the EMBL-EBI GWAS Catalog.

- 277 The left legend indicates the significant SNP-based heritability  $(h^2)$  for the nine DNEs; the right
- 278 legend represents the SNP density of our genetic data throughout the human genome. GWAS
- 279 was performed using the Genome Reference Consortium Human Build 37 (GRCh37). b)
- 280 Phenome-wide association query of the previously identified genomic loci (left panel) in the
- 281 EMBL-EBI GWAS Catalog (via FUMA 1.4.2) shows a brain-dominant genetic architecture. We
- 282 categorized all clinical traits (middle panel) into several high-level categories linked to multiple
- 283 organ systems, neurodegenerative and neuropsychiatric disorders, lifestyle factors, etc. We then
- 284 show the keyword cloud plots for each category (right panel).
- 285

#### 286 The genetic correlation of the nine DNEs

- 287 To understand the shared genetic underpinnings, we estimated the genetic correlation<sup>30</sup> ( $g_c$ )
- 288 (Method 4e) between the nine DNEs, the BAG of nine human organ systems, and six brain
- 289 diseases (AD, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar,
- 290 obsessive-compulsive disorder, schizophrenia; **Supplementary eTable 2**) from the psychiatric 291 genetic consortium.
- 292 We first estimated the  $g_c$  between each pair of DNEs (Fig. 4a). Numerous DNEs
- 293 exhibited strong genetic correlations with each other. Among these, the highest positive genetic
- 294 correlation was obtained between ASD2 and SCZ1 ( $g_c=0.57\pm0.04$ ); the highest negative genetic
- 295 correlations were obtained between ASD2 and ASD1 ( $g_c$ =-0.55±0.04), and between ASD3 and
- 296 SCZ1 ( $g_c$ =-0.51±0.05). We also observed a substantial alignment between the phenotypic
- 297 correlation  $(p_c)$  and the genetic correlation of pairwise DNEs, supporting the long-standing
- 298 Cheverud's Conjecture<sup>40</sup>. However, we identified two exceptions where the observed phenotypic
- 299 and genetic correlations exhibited opposite directions. ASD1 and ASD3 showed a negative
- 300 phenotypic ( $p_c$ =-0.39±0.08) but a positive genetic correlation ( $g_c$ =0.21±0.05); ASD1 and LLD1
- 301 showed a negative phenotypic ( $p_c$ =-0.34±0.09) but a positive genetic correlation ( $g_c$ =0.16±0.07)
- 302 (Supplementary eTable 3). This implies that non-genetic factors may exert opposite influences 303 on the two DNEs.
- 304 Between the nine DNEs and the BAGs across nine human organ systems, we found 305 significant genetic correlations between AD1 ( $g_c=0.23\pm0.05$ ), ASD1 ( $g_c=0.44\pm0.05$ ), LLD2
- 306  $(g_c=0.24\pm0.07)$ , SCZ1  $(g_c=0.26\pm0.06)$ , and the brain BAG, and between ASD1 and the eye BAG
- 307  $(g_c=0.19\pm0.07)$  (Fig. 4b and Supplementary eTable 4).
- 308 Finally, we also found a marginally significant genetic correlation between AD2 and AD ( $g_c=0.22\pm0.12$ ), AD1 and bipolar disorder (BIP,  $g_c=-0.08\pm0.04$ ), and ASD3 and BIP 309
- 310  $(g_c=0.09\pm0.04)$  using GWAS summary statistics from the psychiatric genetic consortium (Fig. 4c

#### 311 and Supplementary eTable 5).

- 312 In summary, the nine DNEs demonstrate substantial genetic correlations among
- 313 themselves and with organ systems beyond the brain, including the eye. These findings highlight
- 314 the interconnectedness of the neuroanatomical patterns and genetic determinants across multiple
- 315 body systems and diseases, suggesting shared underlying etiological factors and potential pleiotropic effects.
- 316
- 317

#### 318 The genetic colocalization of the nine DNEs

- 319 To seek the shared causal variants between two clinical traits (e.g., AD1 vs. LLD2), we
- performed Approximate Bayes Factor colocalization<sup>41</sup> analyses (Method 4f) between the nine 320

321 DNEs (Fig. 4d), with the nine BAGs (Fig. 4e), and the six brain disorders from the psychiatric
 322 genetic consortium (Fig. 4f).

Among the nine DNEs, we detected 53 causal variants (SNPs) exhibiting significant colocalization signals. We showcased the shared causal variant (rs2790099 at 6p21.1) between

ASD2 and SCZ2 with a PP.H4.ABF=0.92. This causal SNP was mapped to the *RUNX2* gene.

The loss of function in RUNX2 causes a rare autosomal dominant skeletal disorder – cleidocranial dysplasia<sup>42</sup>, but it was implicated in ASD or SCZ in previous literature.

Between the nine DNEs and nine BAGs, we identified 16 causal variants (SNPs) exhibiting significant colocalization signals. We showcased the shared causal variant (rs5848503 at 3p22.1) between ASD2 and the brain BAG with a PP.H4.ABF=0.95. One mapped gene in this locus is the *MOPB* gene, which encodes the myelin-associated oligodendrocytes basic protein and is actively involved in the structural constituent of the myelin sheath and nervous system development. This gene was previously implicated in ASD using single-cell genomics<sup>43</sup>, SCZ<sup>44</sup>, amyotrophic lateral sclerosis, and Parkinson's disease<sup>45</sup>.

335 Between the nine DNEs and six brain diseases from the psychiatric genetic consortium, 336 we identified 7 causal variants (SNPs) exhibiting significant colocalization signals. We 337 showcased the shared causal variant (rs9257566 at 6p22.1) between ASD3 and SCZ with a 338 PP.H4.ABF=-0.82. In this locus, multiple olfactory receptor (OR) genes and the dysfunction of the olfactory system were implicated in SCZ<sup>46,47</sup> and ASD<sup>48,49</sup>. For instance, the OR2J2 and 339 340 OR2J3 genes are two protein-coding genes in copy number variants associated with SCZ using 341 microRNA data<sup>50</sup>. The causal SNP (rs9257566) was associated with SCZ and brain IDP, such as 342 white matter microstructural measures (Supplementary eFigure 11). The sensitivity checks on 343 the prior probability (p12) for the three illustrations are shown in **Supplementary eFigure 12a**-344 c. The causal variant, cytogenetic region, and their colocation signal direction (based on  $\beta$ 345 coefficients) are presented in Supplementary eFigure 13a-c and Supplementary eFile 14, 15, 346 and 16, respectively.

The genetic colocalization of the nine DNEs revealed causal genetic variants, indicating
that the same genomic regions may causally influence the expression of these dimensional
neuroimaging endophenotypes. The colocalization findings strengthen the notion that these
DNEs share a fundamental genetic architecture.

351

# 352 The causal relationship of the nine DNEs

We applied bidirectional two-sample Mendelian randomization analyses<sup>51</sup> (**Method 4g**) to depict a causal network between the nine DNEs, the eight BAGs (excluding the brain BAG), and eleven chronic diseases spanning the whole-body system.

For each pair of DNEs, as the GWAS populations completely overlapped, conducting two-sample Mendelian randomization was not feasible<sup>52</sup>. Alternatively, the split-sample GWAS did not yield sufficient statistical power due to the limited number of instrumental variables (VI) available (< 6 SNPs).

Among the nine DNEs and eight BAGs, we found potential causal effects of the eye BAG on LLD1 [P-value= $4.57 \times 10^{-3}$ , OR (95% CI) = 1.14 (1.04, 1.24), number of SNPs=16], the

362 cardiovascular BAG on ASD3 [P-value= $6.04 \times 10^{-3}$ , OR (95% CI) = 1.16 (1.04, 1.24), number of SiVFS=10], the

363 SNPs=34], and the pulmonary BAG on LLD2 [P-value=1.98x10<sup>-3</sup>, OR (95% CI) = 1.14 (1.04,

364 1.25), number of SNPs=49]. No significant causal signals persisted after the Benjamini-

- 365 Hochberg correction in the inverse analyses (Fig. 4g). Details of the results, including all five
- 366 different Mendelian randomization estimators, are shown in Supplementary eFile 17.

- 367 Between the nine DNEs and eleven chronic diseases, encompassing brain-related
- 368 conditions and diseases affecting other organs, we identified a potential causal effect from AD2
- 369 to AD (but not the reversed direction) using the GWAS summary statistics from the psychiatric
- 370 genetic consortium the largest sample size (N=1,126,536) in the AD case-control study [P-
- 371 value= $1.74 \times 10^{-4}$ , OR (95% CI) = 1.25 (1.11, 1.40), number of SNPs=7] (Fig. 4h and
- 372 Supplementary eFigure 17). Details of the results, including all five different Mendelian
- 373 randomization estimators, are shown in **Supplementary eFile 18**.
- The Mendelian randomization results further emphasize the potential benefits of overall
- 375 organ health for brain-related conditions. This highlights the interconnectedness between various
- 376 organ systems and the brain, underscoring the significance of a holistic health and disease
- 377 prevention approach.



378 Figure 4: The genetic correlation, colocalization, and causal networks of the nine DNEs

379

**a)** The genetic correlation between two DNEs ( $g_c$ , lower triangle) mirrors their phenotypic correlation ( $p_c$ , upper triangle). Red-shadowed rectangles highlight two exceptions. The symbol indicates significant results after the Benjamini-Hochberg correction. The symbol # indicates

nominal significance. **b**) genetic correlations between the nine DNEs and nine biological age

gaps (BAG) for nine human organ systems<sup>17</sup>. Solid arrow lines (from the exposure to the 384 385 outcome variables) indicate significant causal relationships after the Benjamini-Hochberg 386 correction; dotted arrow lines show nominal significance (P-value< 0.05). c) genetic correlations 387 between the nine DNEs and six neurodegenerative and neuropsychiatric disorders. d) genetic 388 colocalization was evidenced at one locus (6p21.1) between ASD2 and SCZ1. The signed 389 PP.H4.ABF (0.92) denotes the posterior probability (PP) of hypothesis H4, which suggests that 390 both traits share the same causal SNP (rs2790099). A positive PP indicates concordant  $\beta$  values 391 for both DNEs, while a negative PP implies opposite  $\beta$  values. e) genetic colocalization was 392 evidenced at one locus (3p.22.1) between ASD2 and brain BAG: PP.H4.ABF=0.95 with the 393 cause SNP rs5848503. f) genetic colocalization was evidenced at one locus (6p.22.1) between 394 ASD3 and SCZ case-control GWAS<sup>38</sup> from the psychiatric genetic consortium (European 395 ancestry): PP.H4.ABF=-0.82 with the cause SNP rs9257566. g) the causal network of the nine 396 DNEs with the eight BAGs using bidirectional Mendelian randomization. h) the causal network 397 of the nine DNEs with the eleven chronic diseases (e.g., AD, ADHD, BIP, and SCZ from the

398 psychiatric genetic consortium). The symbols + (OR>1 and  $g_c>0$ ) and – (OR<1 and  $g_c<0$ )

399 represent a positive relationship between the two traits. Abbreviation: AD: Alzheimer's disease;

400 ADHD: Attention-deficit/hyperactivity disorder; ASD: autism spectrum disorder; BIP: bipolar

401 disorder; SCZ: schizophrenia; OCD: Obsessive-compulsive disorder; RA: rheumatoid arthritis;

402 CD: Crohn's disease; T2D: type 2 diabetes; IBD: inflammatory bowel disease; PBC: Primary
403 biliary cirrhosis.

404

383

# 405 The nine DNEs and their PRSs significantly improve prediction for 14 systemic diseases

#### 406 and mortality

407 We investigated the added prediction power of the nine DNEs and their respective PRS (Method 408 4h) for 14 systemic diseases based on the ICD-10 code and mortality outcomes (i.e., the date of 409 death). The definition of the patient and healthy control groups and the mortality outcome are 410 presented in **Method 5**. As anticipated, the prediction performance across all tasks was modest, 411 considering that the DNEs were derived from specific disease populations. However, the DNEs 412 can significantly enhance prediction performance when combined with other commonly 413 available features (e.g., age and sex). 414 In addition to commonly available features, such as age and sex, we found that AD1, 415 ASD1, LLD1, SCZ1, and SCZ2 provided additional prediction power (i.e., incremental  $R^2$ ) for 416 many disease categories (Method 5a). Across the 14 disease categories, the DNEs showed 417 higher incremental  $R^2$  in mental and behavioral disorders (ICD-10 code: F) and diseases linked to 418 the central nervous system (ICD-10 code: G) than other disease categories, proving that the nine 419 DNEs in the general population capture brain disease-related effects. Combining all nine DNEs 420 further improved the incremental  $R^2$ , especially in mental and behavioral disorders ( $R^2=1.01\%$ , 421 P-value=1.74x10<sup>-5</sup>) and diseases linked to the central nervous system ( $R^2$ =0.63%, P-422 value=1.33x10<sup>-5</sup>) (Fig. 5a). Detailed results are shown in Supplementary eTable 6. Results 423 using only the PRS target population are presented in **Supplementary eFigure 18**. 424 Compared to the nine DNEs, the nine PRSs provided smaller additional prediction power. 425 For example, the PRS for ASD3 explained an additional 0.05% of the variance (incremental  $R^2$ ) 426 in diseases associated with the blood and immune systems (P-value=0.03), as well as neoplasms

427 (P-value=0.04). Combining all nine PRSs improves the incremental  $R^2$ , particularly in mental

428 and behavioral disorders ( $R^2=0.3\%$ , P-value=0.047). No results survived the multiple

429 comparisons using the Benjamini-Hochberg method (Fig. 5b). Detailed results are shown in 430 Supplementary eTable 7.

431 We assessed the prediction ability of support vector machines (SVM) at the individual

432 level to classify the 14 disease categories (Method 5b). The highest performance was observed

433 for eye diseases (ICD-code: H0-5). The inclusion of PRSs, DNEs, and the combination of both,

434 along with age and sex as features, resulted in improved classification accuracy for mental and

- 435 behavioral disorders. For example, the accuracy increased from 0.51 to 0.55 and 0.57 for features 436
- of age and sex, 9 DNESs, and 9 PRs, incrementally (Fig. 5c). These findings highlight the added 437 value of incorporating the nine DNEs and PRSs in predicting these disease categories. Detailed
- 438 results are shown in Supplementary eTable 8.
- 439 Finally, we evaluated the prediction power of the nine DNEs and PRSs for mortality risk

440 prediction using the Cox regression. Among these, SCZ1, SCZ1-PRS, ASD1, and AD1-PRS

441 were significantly associated with the risk of mortality (Fig. 5d and Supplementary eTable 9a).

442 Adding SCZ1, AD1-PRS, ASD1, and SCZ1-PRS to age and sex further improved the prediction,

443 but the performance decreased afterward (Fig. 5e). Lastly, incorporating the nine DNEs from the

444 second scan of 1348 participants into the model slightly increased the statistical significance and

445 the HR (Supplementary eTable 9b and c)





448

449 a) The incremental R-squared  $(R^2)$  values of the nine DNEs for predicting 14 systemic disease 450 categories were assessed using the entire UKBB sample, with N=39.178 participants as 451 independent test data. The results focusing only on the PRS target population (N=15,891) can be 452 found in Supplementary eFigure 18. The details to derive  $R^2$  are presented in Method 5a. "ALL" indicates the incremental  $R^2$  contributed by combining the nine DNEs. **b**) The incremental 453 454  $R^2$  of the PRS of the nine DNEs to predict 14 systemic diseases based on the ICD-10 code using 455 only the PRS target sample. c) In the PRS target sample, disease classification accuracy from the independently hold-out test data (N=5581) was assessed using nested cross-validated support 456 457 vector machines in the training/validation/test data (N=10,000) by fitting various sets of features 458 (Cov indicates age and sex). d) The SCZ1, SCZ1-PRS, AD1-PRS, and ASD1 show significant 459 associations with the risk of mortality in the PRS target sample. Age and sex were included as 460 covariates in the Cox proportional hazard model. e) The nine DNEs and PRSs were cumulatively

- 461 included as features in cross-validation for mortality risk prediction. The symbol \* indicates
- 462 significant results that survived the Benjamini-Hochberg correction. The symbol # indicates
- 463 nominal significance. HR: hazard ratio; CI: concordance index.

#### 464 **Discussion**

465 This study investigated the manifestation of nine disease-related brain endophenotypes – derived

466 from four case-control studies via semi-supervised AI methods – in the general population of

467 39,178 participants in UKBB. We assessed commonalities and differences among the nine

468 DNEs, their genetic correlates in the general population, their relationships with the multiple

- 469 human organ systems, and their predictive capacity for 14 systemic disease categories and
- 470 mortality. Our findings demonstrate the clinical applicability of the nine AI-derived DNEs in
- 471 identifying high-risk individuals within the general population prone to developing the four472 major brain disorders.
- 473

# 474 Shared neuroanatomical patterns and genetic determinants across the four brain diseases

#### 475 in the general population

476 Understanding the etiology of neurodegenerative and neuropsychiatric diseases is a complex and 477 ongoing challenge in medical research<sup>15,16,34,36–39,53</sup>. Our results suggest that shared underlying 478 mechanisms and genetic factors may contribute to these disorders' development and progression 479 in the general population. This notion of shared etiology across the four major neurodegenerative 480 and neuropsychiatric diseases, namely ASD, SCZ, LLD, and AD, has garnered considerable 481 attention and reshapes our understanding of these conditions<sup>15,16</sup>.

482 Despite the inherent heterogeneity among neuroanatomical patterns observed in different 483 brain diseases (Fig. 2a), a notable commonality exists regarding their manifestations, which 484 might emanate from underlying mechanisms sharing neuropathologic characteristics and 485 pathways. As an illustration, AD1, LLD2, and SCZ1 exhibited a negative correlation (brain 486 atrophy) with global cortical volume (e.g., bilateral insula and middle frontal gyrus). This aligns 487 with expectations, considering that the UKBB population includes individuals primarily from mid to late life (above 45 years), evidenced by the brain chart of the human lifespan<sup>54</sup>. From an 488 489 etiological standpoint, various factors can contribute to the global cortical volume reduction 490 within the general population, with late-onset neurodegenerative and neuropsychiatric disorders 491 and aging exerting a significant impact. Likewise, ASD2 and SCZ2 exhibited a positive 492 association with the basal ganglia, including the globus pallidum. This could imply the existence 493 of potential protective genetic or environmental factors that collectively contribute to the concept 494 of "brain reserve", which might mitigate volume loss in a portion of the general population. 495 Notably, we previously revealed that individuals predominantly expressing SCZ2 exhibited 496 higher levels of education<sup>4</sup> and higher rates of remission compared to the group primarily 497 influenced by SCZ1. Alternatively, these volume increases might reflect neuropathologic 498 mechanisms, such as disrupted connectivity, which are not necessarily associated with 499 neurodegenerative and neurodevelopmental components related to relatively lower brain 500 volumes.

501 Overall, the commonalities in neuroanatomical patterns across brain diseases can be 502 attributed to several factors. First, shared genetic factors may influence brain structure and function<sup>26,55,56</sup>, contributing to similar neuroanatomical alterations across different diseases. For 503 504 example, in one recent meta-analysis of 193 studies<sup>57</sup>, the authors found a common brain 505 network defined by positive connectivity to the anterior cingulate and insula and negative 506 connectivity to the posterior parietal and lateral occipital cortex among six psychiatric disorders. 507 Genetically, this was largely evidenced by our genetic correlation (Fig. 4a) and colocalization 508 results (Fig. 4d). For instance, ASD2 showed prominent positive genetic overlap with SCZ1.

509 Historically, there has been a long-standing association between ASD and SCZ, leading to the

- 510 notion that autism could be a form of "childhood schizophrenia"<sup>58</sup>. This conceptual link between
- 511 the two conditions has been debated and discussed. Previous case-control neuroimaging studies
- 512 demonstrated divergent structural and functional brain patterns in individuals with ASD
- 513 compared to those with SCZ<sup>59</sup>, largely ignoring the neuroanatomical heterogeneity within each
- 514 condition. Genetic variants that impact key signaling pathways, synaptic function, and neuronal
- 515 connectivity<sup>60,61</sup> could influence multiple disease phenotypes, leading to overlapping
- 516 neuroanatomical patterns. We performed additional MAGMA gene-set analysis<sup>62</sup> to test the
- 517 genetic similarity between ASD2 and SCZ1. The most significant biological pathway underlying  $\Delta SD2$  is the manufacture resulting of locar string (CO 0040012, B value=2.27v10<sup>-5</sup>,  $\theta = 0.22 \pm 0.02$ )
- ASD2 is the negative regulation of locomotion (GO 0040013, P-value= $2.27 \times 10^{-5}$ ,  $\beta$ =0.22±0.02), implicated in biological processes that stop, prevent, or reduce the frequency, rate, or extent of
- 520 locomotion of a cell or organism. The most significant biological pathway for SCZ1 is the
- 521 negative regulation of neurotransmitter transport (GO 0051589, P-value= $1.41 \times 10^{-5}$ ,
- 522  $\beta = 0.22 \pm 0.02$ ), involved in biological processes that downregulate the directed movement of a
- 523 neurotransmitter into, out of, or within a cell. In particular, the latter supports the involvement of
- 524 dopamine and glutamate, two major neurotransmitters in the central nervous system, in
- schizophrenia<sup>63</sup>, and the gross abnormalities of serotonin and dopamine transporter bindings in autism patients<sup>64</sup>.
- AD1 also shared genetic similarities with LLD1, both characterized by spatially extensive brain atrophy and increased brain age. Previous studies found a higher prevalence of depressive symptoms and LLD in individuals with AD compared to the general population<sup>65–67</sup>. The relationship between AD and LLD likely involves multiple factors and may be bidirectional. On the one hand, LLD may increase the risk of developing AD or accelerate the progression of
- cognitive decline in individuals already affected by AD. On the other hand, AD-related changes
- 533 in the brain, such as neuroinflammation and neurochemical imbalances, may worsen depressive
- 534 symptoms in individuals with LLD.
- Recognizing the shared etiology across the four brain diseases challenges traditional diagnostic boundaries and underscores the importance of a broader perspective on clinical presentations and underlying biological mechanisms. This understanding is important for developing targeted and personalized approaches to patient care, leading to more effective
- 539 treatments and interventions.
- 540

# 541 Beyond the brain

542 Our findings strongly concur with a paradigm shift in treating brain diseases. While the

- 543 conventional approach has predominantly concentrated on interventions targeting the brain,
- 544 emerging evidence highlights the critical importance of considering the broader systemic and
- 545 environmental factors that influence disease onset and progression<sup>1,17,18,68,69</sup>.
- 546 Unraveling the intricate interconnections between the brain and other organ systems is 547 crucial in broadening our understanding of brain diseases, as demonstrated by our findings and 548 other findings<sup>17,69</sup>. The brain does not function in isolation but interacts with and is influenced by 549 various physiological systems throughout the body. Our results showed a close genetic
- association and causality between the DNEs and the eye, cardiovascular, and pulmonary systems
- 551 (Fig. 4b and g). These findings parallel previous literature. For instance, eye-related pathological
- 552 changes have been revealed to mirror early signs of neurological and neuropsychiatric
- 553 conditions<sup>70</sup>. The nervous and cardiovascular systems the heart-brain axis are intricately
- 554 linked, with brain regions controlling heart function via sympathetic and parasympathetic

pathways<sup>71</sup>. Dysfunctions in one system can affect the other's function, resulting in brain and 555 556 cardiovascular diseases. The immune system plays a crucial role in modulating inflammation and neuroinflammation, which are implicated in many brain disorders, such as AD<sup>72</sup>, SCZ<sup>73</sup>, and 557 558 depression<sup>74</sup>. Similarly, the gut-brain axis highlights the bidirectional communication between 559 the gut microbiota and the brain, with emerging evidence linking alterations in the gut 560 microbiome to brain diseases such as Parkinson's disease<sup>75</sup> and depression<sup>76</sup>. Understanding and 561 targeting these systemic interactions can modulate disease processes and improve treatment 562 outcomes.

Furthermore, considering environmental and lifestyle factors is essential in treating brain 563 564 diseases<sup>77</sup>. Our previous work<sup>17</sup> has shown that the BAGs of nine human organ systems comply 565 with Cheverud's Conjecture: the phenotypic correlation of two BAGs mirrors their genetic 566 correlations. However, herein we showed that the phenotypic correlation between two DNEs 567 (e.g., ASD1 vs. LLD1) did not reflect their underlying genetic correlation (Fig. 4a), indicating 568 potentially strong environmental and lifestyle factors that exert opposite effects on the two 569 DNEs. Furthermore, an interesting observation from our study was that the heritability estimate 570  $(h^2)$  of early-onset diseases, such as ASD, was higher than that of late-onset diseases, such as 571 LLD, within the three neuropsychiatric disorders. This finding suggests that genetic factors play 572 a more prominent role in developing ASD at a younger age. In contrast, other factors, such as 573 environmental influences, socioeconomic factors, and lifestyle choices, may have a stronger 574 impact on developing LLD later in life. These differential heritability patterns shed light on the 575 complex interplay between genetic and non-genetic factors in the etiology of neurodegenerative 576 and neuropsychiatric disorders across different stages of life. These heritability patterns aligned 577 with a previous study that examined multiple GWAS drawn from more than 200,000 patients for 578 25 brain-associated disorders and 17 phenotypes<sup>16</sup>.

In conclusion, going beyond the brain is crucial for understanding and treating brain
diseases. By considering the connections between the brain and other organ systems,
understanding the impact of environmental and lifestyle factors, and harnessing the power of
advanced AI technologies, we can develop more effective and personalized approaches to
prevent, diagnose, and treat brain diseases.

584

# 585 AI-derived DNEs for precision diagnostics in the general population

The present study leverages cutting-edge, semi-supervised AI methods<sup>78</sup> and open science advancements to enhance our understanding of disease heterogeneity in neurodegenerative and neuropsychiatric disorders<sup>1–3,6,9</sup>. In this context, implementing these AI-derived DNEs at early disease or preclinical stages – in the general population – may facilitate the identification of individuals at risk, and the initiation of proactive interventions before the onset of noticeable symptoms, likely leading to more effective treatments and interventions and better outcomes.

592 The proposed AI-derived DNEs capture intricate brain structure and function variations, 593 often subtle and spatially complex, which traditional diagnostic methods and case-control studies 594 may overlook. By quantifying the neuroanatomical patterns associated with specific brain 595 disorders, DNEs may offer a personalized disease vulnerability assessment, inform interventions 596 at early preclinical stages, and potentially prevent or delay the onset of symptoms. At the 597 individual level, integrating genetic information (i.e., PRSs) with DNEs significantly improves 598 prediction performance for 14 systemic diseases and mortality outcomes (Fig. 5). In addition, our 599 Mendelian randomization analyses supported the well-established endophenotype hypothesis in 600 genetic psychiatry<sup>21</sup> – endophenotype in psychiatric disorders resides inside the causal pathway

from underlying genetics to their exo-phenotypes (i.e., the disease itself), thereby being closer to its etiology. We found that AD2, characterized by focal medial temporal lobe atrophy, exerted a causal relationship with AD. However, we did not find evidence of a reverse causal relationship, suggesting that the underlying genetics may influence the development of AD through the DNE, although it may not be the exclusive pathway contributing to the disease. This highlights the role of genetics in influencing the disease process, particularly through the identified DNE, shedding light on potential pathways and mechanisms involved in AD development.

The present study has several limitations. Firstly, the genetic analysis focused exclusively on common genetic variants. Future investigations should explore the contribution of rare variants to these brain diseases. Secondly, it is important to recognize that our GWAS analyses predominantly involved participants of European ancestry, limiting the generalizability of the genetic findings to other populations with different ancestral backgrounds. Further research efforts are necessary to collect more diverse genetic data and include underrepresented ethnic

614 groups to enhance the generalizability of the findings. Additionally, the validation of the nine

615 DNEs would benefit from additional longitudinal analyses. Fortunately, ongoing efforts to

616 collect longitudinal brain MRI data in UKBB<sup>79</sup> hold promise for providing valuable insights to 617 the scientific community and advancing the field of precision medicine.

618 Together, our AI-derived DNEs have emerged as novel instruments for precision

619 medicine. By capturing the complexity and heterogeneity of brain disorders, DNEs provide a

better understanding of disease pathology, facilitate personalized risk assessment, and hold

621 promise for targeted interventions and population selection.

# 622 Methods

#### 623 Method 1: Study populations

624 Our previous studies used semi-supervised AI models to define the nine DNEs from four disease

- 625 case-control populations. These populations consisted of 865 healthy controls (CN), 1096
- 626 individuals with mild cognitive impairment (MCI), and 414 AD patients from ADNI<sup>19</sup>, 362
- typically developing controls and 307 patients with autism spectrum disorder (ASD) from
- ABIDE<sup>20</sup>, 495 healthy controls and 501 LLD patients from the LLD study<sup>3</sup>, and 364 healthy controls and 307 SCZ patients from PHENOM<sup>4</sup>. For more detailed information about the
- 629 controls and 307 SCZ patients from PHENOM<sup>4</sup>. For more detailed informat 630 characteristics of the study populations, please refer to the original papers.
- 631 The trained AI models were then applied to the UKBB general population as independent 632 data. UKBB is a population-based study of approximately 500,000 people recruited between 633 2006 and 2010 from the United Kingdom. The UKBB study has ethical approval, and the ethics 634 committee is detailed here: https://www.ukbiobank.ac.uk/learn-more-about-uk-
- 635 biobank/governance/ethics-advisory-committee. The current study analyzed 39,178 multimodal
- brain MRI data from UKBB. T1-weighted MRI data were locally processed at the University of
- 637 Pennsylvania; imaging-derived phenotypes (IDP) from diffusion and resting-state functional
- 638 MRI were downloaded from UKBB. In addition, we processed the imputed genotype data<sup>24</sup> from

639 UKBB for GWAS analyses. Last, other clinical traits were also analyzed, including phenotypes

related to nine human organ systems<sup>17,18</sup>. The current work was performed under application

- numbers 35148 and 60698. To unbiasedly evaluate the PRS and machine learning models, wedefined the following populations:
- *Disease case-control populations*: The four datasets used to train the AI models and define the nine DNEs from four brain diseases.
- Independent UKBB general population (N=39,178): The UKBB population in which the trained AI models were applied to derive the nine DNEs.
- *PRS base/target population (split1/split2) (N=15,968)*: the UKBB population was
- divided into two splits (split1 vs. split2) in the split-sample GWAS. To derive the PRS,
  we used the GWAS from split1 as the base data and split2 as the target data. All disease
  and mortality prediction tasks involving PRS used only the PRS target population
  (*N*=15,968).
- 652

# 653 Method 2: Semi-supervised AI methods to derive the nine DNEs

- The methodologies used in the current study to derive the nine DNEs belong to the semisupervised learning algorithms (**Fig. 1a**) pioneered by our group. Refer to a review for details of this type of modeling<sup>78</sup>. In particular, the current study employed the HYDRA<sup>27</sup> and Surreal-
- $657 \quad \text{GAN}^{14} \text{ models.}$
- 658
- 659 (a): HYDRA: HYDRA leverages a widely used discriminative method, i.e., support vector
- 660 machines (SVM), to seek the "1-to-k" mapping. The novelty is that HYDRA extends multiple
- 661 linear SVMs to the non-linear case piecewise, thereby simultaneously serving for classification
- and clustering. Specifically, it constructs a convex polytope by combining the hyperplane from k
- 663 linear SVMs, separating the CN group from the *k* subpopulation of the PT (patient) group.
- Intuitively, each face of the convex polytope can be regarded to encode each subtype, capturing a
- 665 distinct disease effect (Supplementary eMethod 1a).

- 666
- 667

(b): Surreal-GAN: Surreal-GAN<sup>14</sup> dissects underlying disease-related heterogeneity via a deep 668 669 representation learning approach, instead of the discriminative SVM, under the principle of semi-670 supervised clustering – the "I-to-k" mapping. The methodological advance of this method is that 671 Surreal-GAN models disease heterogeneity as a continuous dimensional representation, enforces 672 monotone disease severity in each dimension, and allows the non-exclusive manifestation of all

- 673 dimensions in the same participant (Supplementary eMethod 1b).
- 674

#### 675 **Method 3: Imaging analyses**

676 (a): T1-weighted MRI processing: All images were first corrected for magnetic field intensity 677 inhomogeneity.<sup>80</sup> A deep learning-based skull stripping algorithm was applied to remove extra-

678 cranial material. In total, 145 IDPs were generated in gray matter (GM, 119 ROIs), white matter 679

(WM, 20 ROIs), and ventricles (6 ROIs) using a multi-atlas label fusion method.<sup>81</sup> The ROIs

680 were fit to the four machine learning models to derive the nine DNEs. The imaging quality check 681 is detailed in Supplementary eMethod 2. The other IDPs derived from other MRI modalities

- 682 (i.e., diffusion and resting-state MRI) were downloaded from UKBB.
- 683

684 (b): Neuroanatomical pattern of the nine DNEs: We assessed the neuroanatomical patterns 685 exhibited by the nine DNEs within the general population. Since the DNEs were defined based 686 on the 119 GM ROIs obtained from T1-weighted MRI scans, we aimed to test whether these 687 patterns observed in the disease populations were manifested in the general population. To this 688 end, we used a linear regression model in which each DNE was treated as the dependent 689 variable, while the ROI, age, age-squared, sex, age x sex interaction, age-squared x sex

690 interaction, intracranial volume, brain positions in the scan, and head motion were considered

691 independent variables and covariates. We employed the Bonferroni method for multiple

- 692 comparisons and reported significant results accordingly.
- 693

694 (c): PWAS for the nine DNEs: We performed PWAS to associate the nine DNEs to each of the 695 611 additional phenotypes (Supplementary eFile 1). PWAS excluded the 119 GM ROIs utilized 696 to derive the nine DNEs to prevent any potential circular effects. Instead, the analysis 697 incorporated IDPs from other modalities, such as diffusion and resting-state functional MRI. The 698 same linear or logistic (for binary trait) regression models and multiple comparison corrections

699 were employed.

700 To check the robustness of our PWAS results, we also performed two sensitivity checks: 701 *i*) sex-stratified PWAS for males and females, and *ii*) split-sample PWAS by randomly dividing 702 the entire population into two splits (sex and age did not significantly differ).

703

#### 704 **Method 4: Genetic analyses**

705 We used the imputed genotype data for all genetic analyses, and our quality check pipeline

706 resulted in 31,929 participants with European ancestry and 6,477,810 SNPs. First, we excluded

707 related individuals (up to 2<sup>nd</sup>-degree) from the complete UKBB sample using the KING software

for family relationship inference.<sup>82</sup> We then removed duplicated variants from all 22 autosomal 708

- 709 chromosomes. Individuals whose genetically identified sex did not match their self-
- 710 acknowledged sex were removed. Other excluding criteria were: i) individuals with more than

- 711 3% of missing genotypes; ii) variants with minor allele frequency (MAF) of less than 1%; iii)
- variants with larger than 3% missing genotyping rate; iv) variants that failed the Hardy-
- 713 Weinberg test at  $1 \times 10^{-10}$ . To adjust for population stratification,<sup>83</sup> we derived the first 40 genetic
- principle components (PC) using the FlashPCA software<sup>84</sup>. Details of the genetic quality check
- 715 protocol are described elsewhere  $^{3,17,17,68}$ .
- 716
- 717 (a): GWAS: For GWAS, we ran a linear regression using Plink<sup>85</sup> for each DNE, controlling for
- 718 confounders of age, age-squared, sex, age x sex interaction, age-squared x sex interaction, the
- 719 first 40 genetic principal components, total intracranial volume, three brain position parameters
- in the scanner, and head motion were included, as suggested by a previous study<sup>26</sup>. We adopted the genome-wide P-value threshold ( $5 \times 10^{-8}$ ) and annotated independent genetic signals
- 722 considering linkage disequilibrium (see below).
- To check the robustness of our GWAS results, we also performed several sensitivity checks: *i*) sex-stratified GWAS for males and females, *ii*) split-sample GWAS by randomly
- 725 dividing the entire population into two splits (sex and age did not significantly differ), *iii*)
- comparison of the GWAS results using the 1348 participants (i.e., 1116 European ancestry) that
- 727 were collected for baseline and longitudinal scans from UKBB, *iv*) non-European GWAS
- 728 (N=4783), v) independent GWAS on ADNI whole-genome sequencing data (N=1555) on AD1
- and AD2, vi) concordance with six European ancestry GWAS from the psychiatric genetic
- consortium, including AD, ADHD, ASD, BIP, OCD, and SCZ (Supplementary eTable 2).
- 731

732 **(b):** SNP-based heritability: We estimated the SNP-based heritability  $(h^2)$  using GCTA<sup>31</sup> with 733 the same covariates as in GWAS.

734

735 (c): Annotation of genomic loci: The annotation of genomic loci and mapped genes was 736 performed via FUMA<sup>86</sup>. For the annotation of genomic loci, FUMA first defined lead SNPs 737 (correlation  $r^2 \leq 0.1$ , distance < 250 kilobases) and assigned them to a genomic locus (non-738 overlapping); the lead SNP with the lowest P-value (i.e., the top lead SNP) was used to represent 739 the genomic locus. For gene mappings, three different strategies were considered. First, positional 740 mapping assigns the SNP to its physically nearby genes (a 10 kb window by default). Second, 741 eQTL mapping annotates SNPs to genes based on eQTL associations using the GTEx v8 data<sup>87</sup>. 742 Finally, chromatin interaction mapping annotates SNPs to genes when there is a significant 743 chromatin interaction between the disease-associated regions and nearby or distant genes<sup>86</sup>. The 744 definition of top lead SNP, lead SNP, independent significant SNP, and candidate SNP can be 745 found in Supplementary eMethod 3.

746

# 747 (d): Phenome-wide association queries for the identified loci in the GWAS Catalog: We

748 queried the candidate and significant independent SNPs within each locus in the EMBL-EBI

- GWAS Catalog (query date: 2<sup>nd</sup> June 2023, via FUMA version: v1.5.4) to determine their
- previously identified associations with any other traits. For these associated traits, we further
- 751 mapped them into several high-level categories for visualization purposes.
- 752

# 753 (e): Genetic correlation: We used the LDSC<sup>30</sup> software to estimate the pairwise genetic

- correlation  $(g_c)$  between each pair of DNEs, as well as between the nine DNEs and 9 BAGs of
- multiple organ systems from our previous work<sup>17</sup> and 6 neurodegenerative and neuropsychiatric
- disorders from the psychiatric genetic consortium (**Supplementary eTable 2**). We used the

757 precomputed LD scores from the 1000 Genomes of European ancestry. To ensure the suitability

- of the GWAS summary statistics, we first checked that the selected study's population was
- 759 European ancestry; we then guaranteed a moderate SNP-based heritability  $h^2$  estimate. Notably,
- The LDSC corrects for sample overlap and provides an unbiased estimate of genetic correlation<sup>88</sup>.
- 761 Benjamini-Hochberg procedure was performed to account for multiple comparisons.
- 762

763 (f): Bayesian colocalization: We used the R package (*coloc*) to investigate the genetic

- colocalization signals between two traits at each genomic locus. We employed the Fully Bayesian colocalization analysis using Bayes Factors (*coloc.abf*). This method examines the posterior probability (PP.H4.ABF: Approximate Bayes Factor) to evaluate hypothesis *H4*, which suggests the presence of a single shared causal variant associated with both traits within a specific genomic locus. To determine the significance of the *H4* hypothesis, we set a threshold of PP.H4.ABF>0.8<sup>41</sup>. All other parameters (e.g., the prior probability of  $p_{12}$ ) were set as default. We also performed relevant sensitivity analyses to check the robustness of our findings.
- 770 771

(g): Two-sample bidirectional Mendelian randomization: We could not perform causal
 inference between each pair of DNEs due to the overlapped populations and low sample sizes in

774 split-sample analyses.

We employed a bidirectional, two-sample Mendelian randomization using the
TwoSampleMR package<sup>51</sup> to infer the causal relationships between the nine DNEs and the eight
BAGs across nine human organ systems (excluding the brain). The forward and inverse
Mendelian randomization was performed between each trait pair by switching the exposure and
outcome variables. We applied five different Mendelian randomization methods and reported the
results of inverse variance weighted (IVW) in the main text and the four others (i.e., Egger,
weighted median, simple mode, and weighted mode estimators) in the supplement.

We then performed Mendelian randomization between the nine DNEs and eleven chronic
 diseases spanning the whole-body system. These diseases include four diseases from the
 psychiatric genetic consortium (the ASD and OCD GWAS summary statistics did not provide
 the allele frequency information) and seven diseases unbiasedly curated in our previous work<sup>17</sup>.
 The included clinical traits in our Mendelian randomization are presented in Supplementary
 eTable 10. Benjamini-Hochberg correction was performed for all tested traits.

We performed several sensitivity analyses. First, a heterogeneity test was performed to check for violating the IV assumptions. Horizontal pleiotropy was estimated to navigate the violation of the IV's exclusivity assumption<sup>89</sup> using a funnel plot, single-SNP Mendelian randomization approaches, and Mendelian randomization Egger estimator<sup>90</sup>. Moreover, the leave-one-out analysis excluded one instrument (SNP) at a time and assessed the sensitivity of the results to individual SNP.

794

(h): PRS calculation for the nine DNEs: We calculated the PRS<sup>91</sup> using the GWAS results from the split-sample analyses. The weights of the PRS were defined based on split1 data (base data), and the split2 GWAS summary statistics were used as the target data for PRS calculation. The QC steps for the base data are as follows: *i*) removal of duplicated and ambiguous SNPs for the base data; *ii*) clumping the base GWAS data; *iii*) pruning to remove highly correlated SNPs in the target data; *iv*) removal of high heterozygosity samples in the target data; *v*) removal of duplicated, mismatching and ambiguous SNPs in the target data. After rigorous QC, we used

802 PLINK to generate PRS for the split2 population by adopting the classic C+T method (clumping

+ thresholding). To determine the "best-fit" PRS, we performed a linear regression using the PRS

calculated at different P-value thresholds (0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5), controlling for age,

805 sex, intracellular volume, and the first forty genetic PCs. For each DNE-PRS, we chose the P-

- value threshold with the highest incremental  $R^2$  (Supplementary eFigure 19).
- 807

# 808 Method 5: Disease and mortality outcome prediction.

809 We employed logistic regression to calculate the incremental R-squared ( $R^2$ ) statistics of the nine

- 810 DNEs and PRSs to predict 14 disease categories (a), support vector machines to classify the
- healthy control participants from the disease groups (**b**), and Cox proportional hazard model to
- the ICD-10 code from the UKBB website: <u>https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=40001</u>.
- 814 The healthy control group included participants without any ICD-10-based disease diagnoses.
- 815 The mortality outcome refers to the date of death:

816 <u>https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=40000</u>.

817

818 (a): Pseudo R-squared ( $R^2$ ) statistics of the logistic regression: We built a null model by

819 including age, sex, intracranial volume, brain positions in the scan, and head motion as predictors

820 and the disease as the outcome variable. The alternative model took the disease-specific DNE or

- PRS as one additional predictor. The incremental  $R^2$  was calculated as the difference between the pseudo  $R^2$  of the alternative model and that of the null model, implemented by the *PseudoR2*
- function from the *DescTools* R package (v 0.99.38). For the nine PRSs, we used the PRS target
- sample (N=15,891). For the nine DNEs, we calculated the incremental  $R^2$  using the entire UKBB
- sample (N=39,178) and the PRS target sample (N=15,891).
- 826

827 **(b):** Support vector machines to classify patients vs. controls: Using the PRS target sample 828 (N=15,891), we used 10000 participants in a nested cross-validation (CV) procedure (i.e., CV 829 training/validation/test datasets) to select the hyperparameter *C* in SVM. In addition, we held out 830 5581 participants as an independent test dataset. In **Fig. 5c**, we only presented the classification 831 accuracy from the independent test dataset. The nested cross-validation (CV) procedure<sup>92</sup> 832 involved an outer loop repeated 50 times, where 80% of the data was randomly selected for

1 200% for the data was randomly selected for

- training and 20% for testing. Within each outer loop iteration, an inner loop used 80% of the
- training data for a 10-fold training/validation split.

835 836 (c): Cox proportional hazard model to predict the date of death: To evaluate the predictive 837 capacity of individual DNE and PRS for mortality risk, we employed a Cox proportional hazard 838 model while adjusting for covariates such as age and sex. The hazard ratio (HR) was calculated 839 and reported as the effect size measure that indicates the influence of each DNE or PRS on 840 mortality risk. Furthermore, we incrementally added the most predictive DNE or PRS to the Cox 841 model to determine when the model's performance reached saturation. The concordance index 842 (CI) was utilized to assess the model's performance using a 5-fold cross-validation procedure. 843 All survival analyses were conducted using the lifelines 0.25.7 Python package available online.

# 844 Data Availability

- 845 The GWAS summary statistics corresponding to this study are publicly available on the
- 846 MEDICINE knowledge portal (<u>https://labs.loni.usc.edu/medicine</u>) and the FUMA online
- 847 platform (<u>https://fuma.ctglab.nl/</u>).

# 848 Code Availability

849 The software and resources used in this study are all publicly available:

- MEDICINE: <u>https://labs.loni.usc.edu/medicine</u>, web portal for dissemination
- HYDRA: <u>https://github.com/anbai106/mlni</u>, DNEs for ASD1-3, LLD1-2, SCZ1-2
- Surreal-GAN: <u>https://github.com/zhijian-yang/SurrealGAN</u>, DNEs for AD1-2
- MLNI: <u>https://github.com/anbai106/mlni</u>, SVM classification
- PLINK: https://www.cog-genomics.org/plink/, GWAS, PRS
- FUMA: <u>https://fuma.ctglab.nl/</u>, gene mapping, genomic locus annotation
- GCTA: <u>https://yanglab.westlake.edu.cn/software/gcta/#Overview</u>, heritability estimates
- LDSC: <u>https://github.com/bulik/ldsc</u>, genetic correlation, partitioned heritability
- TwoSampleMR: <u>https://mrcieu.github.io/TwoSampleMR/index.html</u>, MR
- Coloc: <u>https://chr1swallace.github.io/coloc/</u>, Bayesian colocalization
- Lifelines: <u>https://lifelines.readthedocs.io/en/latest/</u>, Survival analyses

# 861 **Competing Interests**

862 None

863

# 864 Authors' contributions

- 865 Dr. Wen has full access to all the data in the study and takes responsibility for the integrity of the
- 866 data and the accuracy of the data analysis.
- 867 Study concept and design: Wen
- 868 Acquisition, analysis, or interpretation of data: Wen
- 869 *Drafting of the manuscript*: Wen
- 870 Critical revision of the manuscript for important intellectual content: all authors
- 871 *Statistical analysis*: Wen

#### 872 **References**

- 873 1. Wen, J. *et al.* Genetic, clinical underpinnings of subtle early brain change along
- Alzheimer's dimensions. 2022.09.16.508329 Preprint at
- 875 https://doi.org/10.1101/2022.09.16.508329 (2022).
- 876 2. Hwang, G. et al. Assessment of Neuroanatomical Endophenotypes of Autism Spectrum
- 877 Disorder and Association With Characteristics of Individuals With Schizophrenia and the
- 678 General Population. *JAMA Psychiatry* (2023) doi:10.1001/jamapsychiatry.2023.0409.
- 879 3. Wen, J. et al. Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical
- 880 Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry*
- 881 (2022) doi:10.1001/jamapsychiatry.2022.0020.
- 4. Chand, G. B. *et al.* Two distinct neuroanatomical subtypes of schizophrenia revealed using
  machine learning. *Brain* 143, 1027–1038 (2020).
- 5. Young, A. L. *et al.* Uncovering the heterogeneity and temporal complexity of
- neurodegenerative diseases with Subtype and Stage Inference. *Nat Commun* **9**, 4273 (2018).
- 886 6. Yang, Z. et al. A deep learning framework identifies dimensional representations of
- Alzheimer's Disease from brain structure. *Nat Commun* **12**, 7065 (2021).
- 888 7. Zhang, X. *et al.* Bayesian model reveals latent atrophy factors with dissociable cognitive
- trajectories in Alzheimer's disease. *Proc Natl Acad Sci USA* **113**, E6535–E6544 (2016).
- 890 8. Vogel, J. W. et al. Four distinct trajectories of tau deposition identified in Alzheimer's
- 891 disease. *Nat Med* **27**, 871–881 (2021).
- 892 9. Wen, J. *et al.* Multi-scale semi-supervised clustering of brain images: Deriving disease
  893 subtypes. *Med Image Anal* **75**, 102304 (2021).

- 10. Ferreira, D., Nordberg, A. & Westman, E. Biological subtypes of Alzheimer disease: A
- systematic review and meta-analysis. *Neurology* **94**, 436–448 (2020).
- 896 11. Hodson, R. Precision medicine. *Nature* **537**, S49–S49 (2016).
- 897 12. Davatzikos, C. et al. Precision diagnostics based on machine learning-derived imaging
- signatures. *Magnetic Resonance Imaging* **64**, 49–61 (2019).
- 13. Leonenko, G. *et al.* Identifying individuals with high risk of Alzheimer's disease using
  polygenic risk scores. *Nat Commun* 12, 4506 (2021).
- 901 14. Yang, Z., Wen, J. & Davatzikos, C. Surreal-GAN: Semi-Supervised Representation
- 902 Learning via GAN for uncovering heterogeneous disease-related imaging patterns. *ICLR*
- 903 (2021).
- Wingo, T. S. *et al.* Shared mechanisms across the major psychiatric and neurodegenerative
  diseases. *Nat Commun* 13, 4314 (2022).
- 906 16. Anttila, V. Analysis of shared heritability in common disorders of the brain. *Science* 360,
  907 eaap8757 (2018).
- Wen, J. *et al.* The Genetic Architecture of Biological Age in Nine Human Organ Systems.
   *medRxiv* 2023.06.08.23291168 (2023) doi:10.1101/2023.06.08.23291168.
- 910 18. Tian, Y. E. et al. Heterogeneous aging across multiple organ systems and prediction of
- 911 chronic disease and mortality. *Nat Med* 1–11 (2023) doi:10.1038/s41591-023-02296-6.
- 912 19. Petersen, R. C. *et al.* Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical
- 913 characterization. *Neurology* **74**, 201–209 (2010).
- 20. Di Martino, A. *et al.* Enhancing studies of the connectome in autism using the autism brain
- 915 imaging data exchange II. Sci Data 4, 170010 (2017).

- 916 21. Kendler, K. & Neale, M. Endophenotype: a conceptual analysis. *Mol Psychiatry* **15**, 789–
- 917 797 (2010).
- 918 22. Cannon, T. D. & Keller, M. C. Endophenotypes in the Genetic Analyses of Mental
- 919 Disorders. Annual Review of Clinical Psychology 2, 267–290 (2006).
- 920 23. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and
- 921 strategic intentions. *Am J Psychiatry* **160**, 636–645 (2003).
- 922 24. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
  923 *Nature* 562, 203–209 (2018).
- 924 25. Alfaro-Almagro, F. et al. Image processing and Quality Control for the first 10,000 brain
- 925 imaging datasets from UK Biobank. *Neuroimage* **166**, (2018).
- 926 26. Elliott, L. T. *et al.* Genome-wide association studies of brain imaging phenotypes in UK
  927 Biobank. *Nature* 562, 210–216 (2018).
- 928 27. Varol, E., Sotiras, A. & Davatzikos, C. HYDRA: Revealing heterogeneity of imaging and
- genetic patterns through a multiple max-margin discriminative analysis framework.
- 930 *NeuroImage* **145**, 346–364 (2017).
- 931 28. Zhang, H., Schneider, T., Wheeler-Kingshott, C. A. & Alexander, D. C. NODDI: Practical
- 932 in vivo neurite orientation dispersion and density imaging of the human brain. *NeuroImage*933 61, 1000–1016 (2012).
- Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
  studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* 47, D1005–D1012
  (2019).
- 937 30. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from
- polygenicity in genome-wide association studies. *Nat Genet* 47, 291–295 (2015).

- 939 31. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide
- 940 Complex Trait Analysis. *Am J Hum Genet* **88**, 76–82 (2011).
- 32. Speed, D., Holmes, J. & Balding, D. J. Evaluating and improving heritability models using
- 942 summary statistics. *Nat Genet* **52**, 458–462 (2020).
- 943 33. Evans, L. M. et al. Comparison of methods that use whole genome data to estimate the
- heritability and genetic architecture of complex traits. *Nat Genet* **50**, 737–745 (2018).
- 945 34. Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals
- 946 identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276–1282 (2021).
- 947 35. Demontis, D. et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the
- genetic architecture and implicate several cognitive domains. *Nat Genet* 55, 198–208
  (2023).
- 950 36. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder.
  951 *Nat Genet* 51, 431–444 (2019).
- 952 37. Mullins, N. et al. Genome-wide association study of more than 40,000 bipolar disorder
- 953 cases provides new insights into the underlying biology. *Nat Genet* **53**, 817–829 (2021).
- 38. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
  schizophrenia. *Nature* 604, 502–508 (2022).
- 956 39. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-
- 957 GC) and OCD Collaborative Genetics Association Studies (OCGAS). Revealing the
- 958 complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol*
- 959 *Psychiatry* **23**, 1181–1188 (2018).
- 960 40. Cheverud, J. M. A COMPARISON OF GENETIC AND PHENOTYPIC
- 961 CORRELATIONS. *Evolution* **42**, 958–968 (1988).

- 962 41. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic
- 963 Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).
- 964 42. Hordyjewska-Kowalczyk, E. et al. Functional analysis of novel RUNX2 mutations
- 965 identified in patients with cleidocranial dysplasia. *Clin Genet* **96**, 429–438 (2019).
- 966 43. Wamsley, B. et al. Molecular cascades and cell-type specific signatures in ASD revealed by
- 967 single cell genomics. 2023.03.10.530869 Preprint at
- 968 https://doi.org/10.1101/2023.03.10.530869 (2023).
- 44. Ayalew, M. *et al.* Convergent functional genomics of schizophrenia: from comprehensive
- 970 understanding to genetic risk prediction. *Mol Psychiatry* **17**, 887–905 (2012).
- 971 45. Siokas, V. et al. Myelin-associated oligodendrocyte basic protein rs616147 polymorphism
- 972 as a risk factor for Parkinson's disease. *Acta Neurologica Scandinavica* **145**, 223–228
- 973 (2022).
- 46. Arnold, S. E. *et al.* Dysregulation of olfactory receptor neuron lineage in schizophrenia. *Arch Gen Psychiatry* 58, 829–835 (2001).
- 47. Turetsky, B. I., Moberg, P. J., Arnold, S. E., Doty, R. L. & Gur, R. E. Low olfactory bulb
  volume in first-degree relatives of patients with schizophrenia. *Am J Psychiatry* 160, 703–
  708 (2003).
- 979 48. Almandil, N. B. *et al.* Exome-wide analysis identify multiple variations in olfactory
- 980 receptor genes (OR12D2 and OR5V1) associated with autism spectrum disorder in Saudi
  981 females. *Frontiers in Medicine* 10, (2023).
- 49. Kuo, P.-H. *et al.* Genome-Wide Association Study for Autism Spectrum Disorder in
  Taiwanese Han Population. *PLOS ONE* 10, e0138695 (2015).

- 984 50. Warnica, W. et al. Copy number variable microRNAs in schizophrenia and their
- 985 neurodevelopmental gene targets. *Biol Psychiatry* **77**, 158–166 (2015).
- 986 51. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the
- 987 human phenome. *eLife* **7**, e34408 (2018).
- 988 52. Sanderson, E. et al. Mendelian randomization. Nat Rev Methods Primers 2, 1–21 (2022).
- 989 53. 23andMe Research Team *et al.* Genome-wide association study of depression phenotypes
- 990 in UK Biobank identifies variants in excitatory synaptic pathways. *Nat Commun* 9, 1470
  991 (2018).
- 992 54. Bethlehem, R. a. I. et al. Brain charts for the human lifespan. 2021.06.08.447489
- 993 https://www.biorxiv.org/content/10.1101/2021.06.08.447489v1 (2021)
- 994 doi:10.1101/2021.06.08.447489.
- 995 55. Wen, J. et al. Novel genomic loci and pathways influence patterns of structural covariance
- 996 in the human brain. 2022.07.20.22277727 Preprint at
- 997 https://doi.org/10.1101/2022.07.20.22277727 (2022).
- 998 56. Zhao, B. et al. Genome-wide association analysis of 19,629 individuals identifies variants
- 999 influencing regional brain volumes and refines their genetic co-architecture with cognitive
- 1000 and mental health traits. *Nat Genet* **51**, 1637–1644 (2019).
- 1001 57. Taylor, J. J. *et al.* A transdiagnostic network for psychiatric illness derived from atrophy
  1002 and lesions. *Nat Hum Behav* 7, 420–429 (2023).
- 1003 58. Zeldovich, L. Cold parenting? Childhood schizophrenia? How the diagnosis of autism has
  1004 evolved over time. *Science* doi: 10.1126/science.aau1206 (2018).
- 1005 59. Moreau, C. A. *et al.* Dissecting autism and schizophrenia through neuroimaging genomics.
- 1006 Brain 144, 1943–1957 (2021).

- Bereczki, E. *et al.* Synaptic markers of cognitive decline in neurodegenerative diseases: a
  proteomic approach. *Brain* 141, 582–595 (2018).
- 1009 61. Jiang, C.-C. et al. Signalling pathways in autism spectrum disorder: mechanisms and
- 1010 therapeutic implications. *Sig Transduct Target Ther* **7**, 1–36 (2022).
- 1011 62. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-
- 1012 Set Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).
- 1013 63. McCutcheon, R. A., Krystal, J. H. & Howes, O. D. Dopamine and glutamate in
- schizophrenia: biology, symptoms and treatment. *World Psychiatry* **19**, 15–33 (2020).
- 1015 64. Nakamura, K. et al. Brain Serotonin and Dopamine Transporter Bindings in Adults With
- 1016 High-Functioning Autism. Archives of General Psychiatry 67, 59–68 (2010).
- 1017 65. Chi, S., Yu, J.-T., Tan, M.-S. & Tan, L. Depression in Alzheimer's disease: epidemiology,
  1018 mechanisms, and management. *J Alzheimers Dis* 42, 739–755 (2014).
- 1019 66. Dafsari, F. S. & Jessen, F. Depression—an underrecognized target for prevention of
- 1020 dementia in Alzheimer's disease. *Transl Psychiatry* **10**, 1–13 (2020).
- 1021 67. Ly, M. et al. Late-life depression and increased risk of dementia: a longitudinal cohort
- 1022 study. *Transl Psychiatry* **11**, 1–10 (2021).
- 1023 68. Wen, J. et al. The Genetic Heterogeneity of Multimodal Human Brain Age. bioRxiv
- 1024 2023.04.13.536818 (2023) doi:10.1101/2023.04.13.536818.
- 1025 69. Zhao, B. *et al.* Heart-brain connections: Phenotypic and genetic insights from magnetic
  1026 resonance images. *Science* 380, abn6598 (2023).
- 1027 70. Woo, M. Eyes hint at hidden mental-health conditions. Eyes hint at hidden mental-health
- 1028 *conditions* https://www.nature.com/articles/d41586-019-01114-9 (2019).

- 1029 71. Tahsili-Fahadan, P. & Geocadin, R. G. Heart–Brain Axis. *Circulation Research* 120, 559–
  1030 572 (2017).
- 1031 72. Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease:
- 1032 where do we go from here? *Nat Rev Neurol* **17**, 157–172 (2021).
- 1033 73. Murphy, C. E., Walker, A. K. & Weickert, C. S. Neuroinflammation in schizophrenia: the
- role of nuclear factor kappa B. *Transl Psychiatry* **11**, 1–13 (2021).
- 1035 74. Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary
- 1036 imperative to modern treatment target. *Nat Rev Immunol* **16**, 22–34 (2016).
- 1037 75. Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease
- 1038 from basic research to the clinic. *Nat Rev Neurol* **18**, 476–495 (2022).
- 1039 76. Morais, L. H., Schreiber, H. L. & Mazmanian, S. K. The gut microbiota–brain axis in
  1040 behaviour and brain disorders. *Nat Rev Microbiol* 19, 241–255 (2021).
- 1041 77. Tost, H., Champagne, F. A. & Meyer-Lindenberg, A. Environmental influence in the brain,
- 1042 human welfare and mental health. *Nat Neurosci* **18**, 1421–1431 (2015).
- 1043 78. Wen, J. et al. Subtyping brain diseases from imaging data. Preprint at
- 1044 https://doi.org/10.48550/arXiv.2202.10945 (2022).
- 1045 79. UKBB, U. Ambitious project announced to create the world's largest longitudinal imaging
- 1046 dataset. https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/ambitious-
- 1047 project-announced-to-create-the-world-s-largest-longitudinal-imaging-dataset.
- 1048 80. Tustison, N. J. et al. N4ITK: improved N3 bias correction. IEEE Trans. Med. Imaging 29,
- 1049 1310–1320 (2010).

- 1050 81. Doshi, J. et al. MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration
- algorithms and parameters, and locally optimal atlas selection. *Neuroimage* 127, 186–195
  (2016).
- 1053 82. Manichaikul, A. et al. Robust relationship inference in genome-wide association studies.
- 1054 *Bioinformatics* **26**, 2867–2873 (2010).
- 1055 83. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population
- 1056 stratification in genome-wide association studies. *Nat Rev Genet* **11**, 459–463 (2010).
- 1057 84. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-
- scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).
- 1059 85. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
  1060 Linkage Analyses. *Am J Hum Genet* 81, 559–575 (2007).
- 1061 86. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
- annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 1063 87. The GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 45,
  1064 580–585 (2013).
- 1065 88. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.
  1066 *Nat Genet* 47, 1236–1241 (2015).
- 1067 89. Bowden, J. *et al.* A framework for the investigation of pleiotropy in two-sample summary
  1068 data Mendelian randomization. *Stat Med* 36, 1783–1802 (2017).
- 1069 90. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
- 1070 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*
- **44**, 512–525 (2015).

- 1072 91. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk
- 1073 score analyses. *Nat Protoc* **15**, 2759–2772 (2020).
- 1074 92. Wen, J. et al. Convolutional neural networks for classification of Alzheimer's disease:
- 1075 Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).

1076

1077

#### 1078 Acknowledgments

- 1079 We want to express our sincere gratitude to the UK Biobank team for their invaluable
- 1080 contribution to advancing clinical research in our field. We extend our gratitude to the
- 1081 psychiatric genetic consortium (PGC: <u>https://pgc.unc.edu/</u>) for their generosity in sharing the
- 1082 GWAS summary statistics with the broader scientific community. This study used the UK
- 1083 Biobank resource under Application Numbers: 35148 and 60698. Additionally, we extend our
- 1084 appreciation to the psychiatric genetic consortium for their valuable contribution to sharing the
- 1085 GWAS summary statistics with the scientific community. Lastly, we acknowledge the
- 1086 collaboration between the University of Southern California, the University of Pennsylvania, and
- 1087 the University of Melbourne in conducting this research. We gratefully acknowledge the support
- 1088 of the iSTAGING consortium, funded by the National Institute on Aging through grant RF1
- 1089 AG054409 at the University of Pennsylvania (CD). We also acknowledge the funding provided
- 1090 by the National Institute of Biomedical Imaging and Bioengineering at the University of
- 1091 Southern California through grant 5P41EB015922-25 (AT). Additionally, we acknowledge the
- 1092 funding program from the Rebecca L. Cooper Foundation at the University of Melbourne (AZ).